{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Each patient is classified as having experienced grade 3 or higher CTC version 4 toxicity if at any time during protocol therapy such an event is observed for the individual.","groups":[{"description":"These are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular diagnosed disease. Therefore, both Rhabdomyosarcoma and Wilms Tumor are combined in this analysis.","id":"OG000","title":"Rhabdomyosarcoma and Wilms Tumor"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients diagnosed with Rhabdomyosarcoma or Wilms Tumor are combined in this analysis.","reportingStatus":"POSTED","timeFrame":"six cycles of chemotherapy; expected to be 126 days of treatment","title":"The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,","type":"SECONDARY","unitOfMeasure":"Participants"}